Citigroup Lowers Kenvue (NYSE:KVUE) Price Target to $21.00

Kenvue (NYSE:KVUEGet Free Report) had its price objective lowered by investment analysts at Citigroup from $25.00 to $21.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Citigroup’s price target suggests a potential upside of 0.77% from the stock’s current price.

Several other research firms also recently issued reports on KVUE. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a “buy” rating to a “hold” rating and lowered their price objective for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Piper Sandler upgraded shares of Kenvue from a “neutral” rating to an “overweight” rating and upped their price target for the company from $21.00 to $26.00 in a research report on Monday, January 6th. Jefferies Financial Group assumed coverage on shares of Kenvue in a report on Tuesday, September 24th. They set a “buy” rating and a $27.00 price target on the stock. JPMorgan Chase & Co. increased their price objective on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Finally, Royal Bank of Canada raised Kenvue from a “hold” rating to a “moderate buy” rating in a research report on Monday, December 9th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $23.18.

Read Our Latest Report on KVUE

Kenvue Price Performance

Kenvue stock traded down $0.19 during mid-day trading on Wednesday, reaching $20.84. The company had a trading volume of 4,832,283 shares, compared to its average volume of 8,578,188. The business has a fifty day simple moving average of $22.54 and a 200 day simple moving average of $21.65. The company has a market cap of $39.96 billion, a P/E ratio of 37.89, a P/E/G ratio of 2.02 and a beta of 1.46. Kenvue has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUEGet Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. During the same quarter last year, the business posted $0.31 EPS. Kenvue’s revenue for the quarter was down .4% on a year-over-year basis. On average, equities research analysts predict that Kenvue will post 1.07 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in KVUE. State Street Corp lifted its holdings in Kenvue by 16.8% during the third quarter. State Street Corp now owns 127,213,940 shares of the company’s stock valued at $2,942,458,000 after purchasing an additional 18,283,473 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in Kenvue by 8.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company’s stock valued at $2,011,832,000 after buying an additional 7,115,374 shares in the last quarter. Holocene Advisors LP grew its stake in Kenvue by 75.5% in the 3rd quarter. Holocene Advisors LP now owns 13,886,454 shares of the company’s stock valued at $321,194,000 after buying an additional 5,975,392 shares in the last quarter. M&G PLC raised its holdings in Kenvue by 538.0% during the 3rd quarter. M&G PLC now owns 4,341,172 shares of the company’s stock valued at $99,847,000 after acquiring an additional 3,660,730 shares during the period. Finally, FMR LLC lifted its position in shares of Kenvue by 2.3% during the third quarter. FMR LLC now owns 137,915,493 shares of the company’s stock worth $3,189,985,000 after acquiring an additional 3,075,019 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Company Profile

(Get Free Report)

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Featured Stories

Analyst Recommendations for Kenvue (NYSE:KVUE)

Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.